Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Completed 30Terminated 15Recruiting 8Unknown 4Active not recruiting 4Not yet recruiting 3Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 1

Conditions

Leukemia, Myeloid, Acute 39Myelodysplastic Syndromes 15Leukemia, Myelomonocytic, Chronic 11Leukemia 4Myeloproliferative Disorders 3Anemia, Refractory, with Excess of Blasts 3Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Thrombocytosis 1Thrombocythemia, Essential 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Cyclophosphamide 16fludarabine 9fludarabine phosphate 8Whole-Body Irradiation 5Rituximab 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Busulfan 5Melphalan 4Etoposide 4Cytarabine 4Azacitidine 4AP 1903 reagent 4ruxolitinib 3ibrutinib 3Tacrolimus 3Prednisone 3Methotrexate 3Mesna 3Cyclosporine 3venetoclax 2pegaspargase 2obinutuzumab 2ivosidenib 2Vincristine 2Patient Reported Outcome Measures 2Observation 2Mercaptopurine 2Leucovorin 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia × Azacitidine × Clear all
NCT02530463 2026-03-05

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
99 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT02677922 2026-02-19

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Celgene

Phase 1/2 Active not recruiting
130 enrolled 38 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT03173248 2025-11-10

AGILE

Servier

Phase 3 Active not recruiting
146 enrolled 11 charts 1 FDA
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT04090736 2025-03-17

PEVOLAM

PETHEMA Foundation

Phase 3 Active not recruiting
302 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡